Results 81 to 90 of about 55,251 (223)
Background The Bacille Calmette-Guérin (BCG) vaccine, developed in the early 20th century, remains the only widely approved prophylactic against tuberculosis (TB). It was derived from an attenuated strain of Mycobacterium bovis.
Paloma Rezende Corrêa +4 more
doaj +1 more source
Exploring the Causes of Low Immunization Status in School Going Children [PDF]
Background: Although a definitive immunization program has been advocated for children in our country, the immunization coverage is far from satisfactory. There is paucity of survey studies related to immunization pattern.
Inamdar, M +3 more
core +1 more source
The impact of Bacille Calmette-Guerin shortage on immunisation practice and policies in Europe - A Paediatric Tuberculosis Network European Trials Group (ptbnet) survey [PDF]
Background: Recent reports indicate an ongoing BCG shortage that may influence immunisation practice. This study aimed to determine current availability of BCG vaccine across Europe, and implications on immunisation practices and policies in Europe ...
Kontturi, Antti +6 more
core +1 more source
SUBDUE‐3: SUB‐urothelial DUrvalumab‐89zirconium injEction; a phase 0 biodistribution study protocol
BJU International, EarlyView.
Kevin G. Keane +9 more
wiley +1 more source
This study reveals the prevalence of bovine TB from vendor's milk and herd‐level testing using molecular approach: PCR and ELISA test highlighting the risk factor dynamics that shape bovine tuberculosis (bTB) occurrence in Sylhet region of Bangladesh. The findings advance understanding of bTB for diagnostics and surveillance strategies.
Lipi Rani Basak +8 more
wiley +1 more source
BCG (Bacille Calmette-Guérin), an attenuated vaccine derived from Mycobacterium bovis, is the current vaccine of choice against tuberculosis (TB). Despite its protection against active TB in children, BCG has failed to protect adults against TB infection
Adeliane C da Costa +3 more
doaj +1 more source
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick +13 more
wiley +1 more source
OBJETIVO: A vacina BCG é utilizada desde 1921, embora ainda apresente controvérsias e aspectos não esclarecidos. O objetivo do artigo foi analisar aspectos relacionados ao efeito protetor da primeira e segunda doses da vacina BCG e as políticas de ...
Susan M Pereira +3 more
doaj +1 more source
Factors affecting home delivery in rural Tanzania [PDF]
BACKGROUND\ud \ud Studies of factors affecting place of delivery have rarely considered the influence of gender roles and relations within the household.
Mrisho, M +6 more
core +2 more sources
Background Bacille Calmette-Guerin (BCG) is currently the only available vaccine against tuberculosis (TB) and comprises a heterogeneous family of sub-strains with genotypic and phenotypic differences. The World Health Organization (WHO) affirms that the
Degrave Wim M +8 more
doaj +1 more source

